生长抑素受体2在结直肠癌中的表达

中国临床药理学与治疗学 ›› 2013, Vol. 18 ›› Issue (10): 1100-1104.

生长抑素受体2在结直肠癌中的表达

程元光¹, 吴佩²

¹安徽医科大学第三附院胃肠外科,合肥市第一人民医院,合肥 230061,安徽;
²皖南医学院附属弋矶山医院普外科,芜湖241001,安徽

收稿日期:2013-06-06 修回日期:2013-09-10 出版日期:2013-10-26 发布日期:2013-09-30
通讯作者: 吴佩,男,主任医师,教授,研究方向:胃肠肿瘤。Tel: 0553-5739343 E-mail: wp5708@sina.com
作者简介:程元光,男,硕士研究生,主治医师,研究方向:胃肠肿瘤。Tel: 13956002802 E-mail: 13956002802@163.com

Expression of somatostatin receptor type 2 in colorectal cancer

CHENG Yuan-guang¹, WU Pei²

¹The Third Affiliated Hospital of Anhui Medical University,the First People's Hospital of Hefei, Hefei 230061, Anhui, China,
²The First Affiliated Hospital of Wannan Medical College, Wuhu 241001, Anhui, China

Received:2013-06-06 Revised:2013-09-10 Online:2013-10-26 Published:2013-09-30

摘要/Abstract

摘要： 目的:检测生长抑素Ⅱ型受体(SSR2)mRNA在结直肠癌组织中的表达并研究其在结直肠癌发生、发展中的作用。方法:采用逆转录聚合酶链反应(Reverse transcription-PCR,RT-PCR)方法检测37例结直肠癌患者癌远旁黏膜、癌近旁黏膜、肿瘤组织中SSR2 mRNA的表达情况,分析不同组织表达阳性率及表达强度的差别。结果:SSR2 mRNA在癌远旁黏膜、癌近旁黏膜、癌组织表达阳性率分别为100%、91.9%、83.8%,表达阳性率差异有统计学意义(P=0.038),结直肠癌组织中SSR2 mRNA表达强度明显低于正常黏膜(P=0.021)。在结直肠癌组织中SSR2 mRNA的表达阳性率与肿瘤的分化程度、Dukes分期相关(P=0.021,P=0.005),其表达强度也与肿瘤的分化程度、Dukes分期相关(P=0.013,P=0.019),而其表达率及表达强度与病人年龄、性别、肿瘤大小、部位及血清CEA的水平无显著相关性。结论:SSR2 mRNA在结直肠癌中表达明显降低,其表达率及表达强度与肿瘤的分化程度、Dukes分期相关,可能与肿瘤的发生、发展有一定的关联。

关键词: 大肠癌, 生长抑素受体, 生长抑素受体2, 逆转录聚合酶反应

Abstract: AIM: To investigate the expression and role of somatostatin receptor subtype2 (SSR2) in the pathogenesis and progression of human colorectal cancer (CRC).METHODS: 37 cases of CRC in inpatients were identified and all tissue specimens of the cases after surgical resection immediately were selected.The tissue specimens including remote mucosa of tumors (10 cm beyond the tumor),adjacent mucosa of tumors(within 2 cm of the tumor),tumors.The expression of SSR2 mRNA in the specimens were detected by reverse transcription polymerase chain reaction(RT-PCR) and the positive rate and the expression in the specimens were analyzed.RESULTS: The SSR2 mRNA expression rate of the samples shows remote mucosa of tumor 100%(37/37),adjacent mucosa of tumor 91.9%(34/37) and tumor 83.8% (31/37). Compared with the nomal colorectal mucosae,the expression rate and expression intensity of tumor were decreased significantly (P=0.038, P=0.021). The significant correlation of SSR2 mRNA expression rate and intensity in tumor differentiation (P=0.021,P=0.013) and tumor stage (P=0.005,P=0.019) were found,while there was no significant correlation in the expression of SSR2 mRNA and other clinic pathological parameters such as age,sex,tumor size,site and the level of CEA in serum.CONCLUSION: The expression of SSR2 mRNA in tumor is decreased significantly. SSR2 mRNA expression rate and expression intensity of tumor are correlated with the tumor differentiation and stage,and SSR2 may play an important role in the pathogenesis and progression of CRC.

Key words: Colorectal cancer, Somatostatin receptor, Somatostatin receptor 2, RT-PCR

中图分类号:

R735. 34

程元光, 吴佩. 生长抑素受体2在结直肠癌中的表达[J]. 中国临床药理学与治疗学, 2013, 18(10): 1100-1104.

CHENG Yuan-guang, WU Pei. Expression of somatostatin receptor type 2 in colorectal cancer[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(10): 1100-1104.

参考文献

[1] 吴佩, 闫竞一, 茆家定, 等. 胃泌素、生长抑素对大肠癌细胞周期的调控作用[J].中华实验外科杂志,2005, 22(12): 1586.
[2] 许小兵, 张晓华, 杨妙芳, 等. PTPeta介导生长抑素对SMMC7721生长抑制作用的实验研究[J]. 中国临床药理学与治疗学,2011,16(11): 1222-1226.
[3] Hagemeister A, Kittilson JD, Bergan HE, et al. Rainbow trout somatostatin receptor subtypes SSTR1A, SSTR1B, and SSTR2 differentially activate the ERK and PI3K signaling pathways in transfected cells[J]. J Mol Endocrinol, 2010, 45(5): 317-327.
[4] Ben-Shlomo A, Melmed S. Pituitary somatostatin receptor signaling[J]. Trends Endoerinol Metab,2010, 21(3): 123-133.
[5] Righi L, Volante M, Tacaglione V, et al. Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218'clinically aggressive' case[J]. Ann Oncol, 2010, 21(3): 548-555.
[6] Johnson MD, O'Connell MJ, Silberstein H, et al. Differential Expression of Somatostatin Receptors, P44/42 MAPK, and mTOR Activation in Medulloblastomas and Primitive Neuroectodermal Tumors[J]. Appl Immunohistochem Mol Morphol,2013 Feb 28. [Epub ahead of print]
[7] Msaouel P, Galanis E, Koutsilieris M.Somatostatin and somatostatin receptors: implications for neoplastic growth and cancer biology[J]. Expert Opin Investig Drugs,2009, 18(9):1297-1316.
[8] Kubota A, Yamada Y, Kagimoto S, et al. Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors[J]. J Clin Invest, 1994, 93(3): 1321-1325.
[9] Nie GY, Wang J, Li Y, et al. Construction and application of a multispecific competitor to quantify mRNA of matrix metallopro-teinases and their tissue inhibitors in small human biopsies[J]. J Biochem Biophys Methods,1999, 40(3): 81-99.
[10] Garinis GA, Manolis EN, Spanakis NE, et al. High frequency of concomitant nm23-H1 and E-cadherin transcriptional inactivation in primary non- inheriting colorectal carcinomas[J]. J Mol Med,2003, 81(4): 256-263.
[11] Smitha MC, Maggi M, Orlando C. Somatostatin receptors in non-endocrine tumours[J]. Dig Liver Dis,2004, 36(Suppl 1): S78-85.
[12] Colucci R, Blandizzi C, Ghisu N, et al. Somatostatin inhibits colon cancer cell growth through cyclooxygenase-2 down regulation[J]. Br J Pharmacol,2008, 155(2): 198-209.
[13] Dy DY, Whitehead RH, Morris DL. SMS 201.995 inhibits in vitro and in vivo growth of human colon cancer[J]. Cancer Res,1992, 52(4): 917-923.
[14] Dimitroulopoulos D, Xinopoulos D, Tsamakidis K, et al. Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: randomized placebo-controlled trial[J]. World J Gastroenterol,2007, 13(23): 3164-3170.
[15] Raggi CC, Cianchi F, Valanzano R, et al. Prognostic value of somatostatin receptor subtype 2 expression in colorectal cancer[J]. Regul Pept,2005, 132(1/2/3): 23-26.
[16] Smith MC, Maggi M,Orlando C. Somatostatin receptors in non-endocrine tumours[J]. Dig Liver Dis,2004, 36(Suppl 1): S78-S85.
[17] Casini Raggi C, Calabrò A, Renzi D, et al. Quantitative evaluation of somatostatin receptor subtype 2 expression in sporadic colorectal tumor and in the corresponding normal mucosa[J]. Clin Cancer Res,2002, 8(2): 419-427.
[18] Evangelou I, Petraki C, Msaouel P, et al. Immunohistochemical expression of somatostatin receptor subtypes 2 and 5 in colorectal cancer[J]. Eur J Clin Invest,2012, 42(7): 777-783.